Skip to main content
INVENTISBIO CO., LIMITED. logo

INVENTISBIO CO., LIMITED. — Investor Relations & Filings

Ticker · 688382 ISIN · CNE100005Q22 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 446 across all filing types
Latest filing 2023-08-21 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688382

About INVENTISBIO CO., LIMITED.

https://www.inventisbio.com/

InventisBio Co., Ltd. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative small molecule therapeutics. The company focuses on addressing unmet medical needs in oncology and metabolic diseases. Its research and development pipeline includes several high-potential candidates, such as befotertinib, a third-generation EGFR tyrosine kinase inhibitor for non-small cell lung cancer, and garsorasib, a potent KRAS G12C inhibitor. Additionally, the company is developing D-0502, an oral selective estrogen receptor degrader for breast cancer, and D-0120, a selective URAT1 inhibitor for the treatment of hyperuricemia and gout. InventisBio leverages its proprietary drug discovery platform and global clinical development expertise to advance a diverse portfolio of targeted therapies aimed at improving patient outcomes through precision medicine.

Recent filings

Filing Released Lang Actions
益方生物关于使用部分闲置募集资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by a company regarding the use of part of its idle raised funds for cash management. It details the board meeting resolutions, investment purpose, risk control measures, and approvals related to the use of idle raised funds for purchasing safe, liquid, principal-protected financial products. The document references regulatory approvals and compliance with securities regulations. It does not contain financial statements or detailed financial results but is a disclosure about the company's financing fund usage and management decisions. The document length is 3697 characters, which is relatively short and consistent with an announcement rather than a full report. This fits the category of Capital/Financing Update (CAP), as it updates on the company's use of raised capital and cash management activities.
2023-08-21 Chinese
益方生物2022年限制性股票激励计划预留授予激励对象名单（授予日）
Capital/Financing Update Classification · 95% confidence The document is a short announcement (764 characters) detailing the reserved grant of restricted stock incentive plan for 2022, including the list of incentive recipients and related percentages. It is issued by the company's board and dated August 21, 2023. There is no detailed financial data, no full report, and no mention of an attached or published report. The content focuses on stock incentive plan details, which is a capital/financing update related to share-based compensation. Therefore, the document fits best under Capital/Financing Update (CAP).
2023-08-21 Chinese
上海信公轶禾企业管理咨询有限公司关于益方生物科技（上海）股份有限公司2022年限制性股票激励计划预留授予相关事项之独立财务顾问报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Independent Financial Advisor Report" regarding the 2022 Restricted Stock Incentive Plan of Yifang Biotechnology (Shanghai) Co., Ltd. It is prepared by Shanghai Xingong Yihe Enterprise Management Consulting Co., Ltd. The content includes detailed explanations about the stock incentive plan, approval procedures, grant conditions, and the advisor's verification opinions. It is a standalone advisory report related to a specific equity incentive plan, not a general annual or interim financial report, earnings release, or regulatory filing. The document is lengthy (over 8,000 characters) and contains substantive content, not merely an announcement or certification. This fits the category of an Audit Report / Information (AR), which includes standalone audit or advisory reports related to company financial or equity matters but excludes full annual reports. Therefore, the appropriate classification is AR with high confidence. FY 2023
2023-08-21 Chinese
益方生物独立董事关于公司第一届董事会2023年第四次会议相关议案的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion on several board meeting proposals related to the company's 2023 fourth board meeting. It discusses approval of a special report on the use of raised funds for the half-year 2023 period, approval of cash management of idle raised funds, and approval of a restricted stock incentive plan grant. The document is not a full financial report but rather an opinion on board meeting agenda items and related proposals. It is not an announcement of voting results, nor a full annual or interim report. It is a governance-related document reflecting board-level decisions and opinions on corporate governance matters such as fundraising use and stock incentive plans. Therefore, it fits best under Board/Management Information (MANG) as it relates to board meeting agenda and approvals.
2023-08-21 Chinese
益方生物2023年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2023 年半年度报告' which translates to '2023 Semi-Annual Report'. It contains detailed financial data, management discussion and analysis, company business overview, risk factors, and product pipeline updates. The document length is 15,000 characters, indicating a comprehensive report rather than a brief announcement. It includes actual financial statements and substantive financial data for the first half of 2023 (1-6 months). The presence of management discussion and analysis and detailed financial metrics confirms it is a periodic financial report for less than a full fiscal year. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2023
2023-08-21 Chinese
益方生物关于向2022年限制性股票激励计划激励对象授予预留部分限制性股票的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the granting of reserved restricted shares under the company's 2022 restricted stock incentive plan. It details the number of shares granted, the grant date, the price, the approval process, legal and financial advisor opinions, and compliance with relevant laws and regulations. The content focuses on the stock incentive plan and the granting of shares to employees or management, which is a capital/financing activity related to share issuance and equity incentives. It is not a full financial report, earnings release, or management discussion. It is also not a regulatory filing or announcement of a report publication. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length (8832 characters) and detailed content support this classification with high confidence.
2023-08-21 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.